**Supplementary Figure 1. Rates of Remission and Low Disease Activity/Remission**

Supplementary Table 1. Relationship Between Remission States, and End-Point Low HAQ Scores In Patients With An Initial HAQ ≥0.50

Group	Remission/LDA Status	Patients	Mean End-Point DAS28 (95% CI)	End-Point HAQ		
				HAQ ≤0.5	*Specificity*	*Sensitivity*
CARDERA (n=351)	*Sustained Remission*	24 (7%)	1.84 (1.67, 2.01)	17/72	98%	24%
	Point Remission	115 (33%)	2.71 (2.48, 2.95)	56/72	79%	78%
	End-Point Remission	72 (21%)	1.93 (1.81, 2.05)	42/72	89%	58%
	Sustained LDA/Remission	41 (12%)	2.05 (1.88, 2.23)	29/72	96%	40%
	Point LDA/Remission	163 (46%)	3.04 (2.84, 3.24)	64/72	65%	89%
	End-Point LDA/Remission	102 (29%)	2.21 (2.09, 2.33)	53/72	82%	74%
TACIT (n=187)	*Sustained Remission*	10 (5%)	1.66 (1.32, 2.00)	5/27	97%	21%
	Point Remission	76 (42%)	2.86 (2.57, 3.15)	17/27	63%	63%
	End-Point Remission	38 (21%)	1.95 (1.79, 2.12)	14/27	85%	52%
	Sustained LDA/Remission	16 (9%)	1.77 (1.50, 2.04)	7/27	95%	29%
	Point LDA/Remission	114 (62%)	3.22 (2.98, 3.46)	25/27	44%	93%
	End-Point LDA/Remission	62 (34%)	2.32 (2.16, 2.47)	19/27	72%	70%
RA Centre (n=563)	*Sustained Remission*	20 (4%)	1.54 (1.34, 1.73)	6/45	97%	13%
	Point Remission	289 (51%)	3.05 (1.34, 1.73)	37/45	50%	82%
	End-Point Remission	143 (25%)	2.72 (2.58, 2.85)	31/45	78%	70%
	Sustained LDA/Remission	54 (10%)	2.06 (1.91, 2.21)	13/45	92%	29%
	Point LDA/Remission	398 (71%)	3.29 (3.21, 3.38)	43/45	32%	96%
	End-Point LDA/Remission	241 (43%)	3.00 (2.89, 3.10)	37/45	61%	82%

Sustained remission: in TACIT and CARDERA this is a DAS28-ESR<2.6 from 6-months onwards and in the RA Centre at all time-points; point remission: a DAS28-ESR <2.6 at any time point; end-point remission: a DAS28-ESR <2.6 at the final time-point in each cohort. For LDA/remission a DAS28-ESR cut-off ≤3.2 is used.